Analysis Biovica: Good progress in FDA discussions

Biovica has communicated how DiviTum will be clinically validated to complete a 510(k)-filing with the FDA. While this means a slight delay compared with the previous target, we view the new plan as promising and credible.

Read the full report (Swedish) here.